Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial

BACKGROUND: No standard treatments are available for advanced thymic epithelial tumours after failure of platinum-based chemotherapy. We investigated the activity of sunitinib, an orally administered tyrosine kinase inhibitor. METHODS: Between May 15, 2012, and Oct 2, 2013, we did an open-label phas...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Lancet Oncol
Hoofdauteurs: Thomas, Anish, Rajan, Arun, Berman, Arlene, Tomita, Yusuke, Brzezniak, Christina, Lee, Min-Jung, Lee, Sunmin, Ling, Alexander, Spittler, Aaron J, Carter, Corey A, Guha, Udayan, Wang, Yisong, Szabo, Eva, Meltzer, Paul, Steinberg, Seth M, Trepel, Jane B, Loehrer, Patrick J, Giaccone, Giuseppe
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2015
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4401497/
https://ncbi.nlm.nih.gov/pubmed/25592632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)71181-7
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items